Use of primary human immune cells for Advanced Therapy POC studies_v1

  • Research type

    Research Study

  • Full title

    Use of primary human immune cells for the development of therapeutic approaches (cell and gene therapies) to treat a range of diseases including solid tumour indications in oncology.

  • IRAS ID

    352867

  • Contact name

    Tom Payne

  • Contact email

    tom.payne@laverocktx.com

  • Sponsor organisation

    Laverock Therapeutics

  • Duration of Study in the UK

    10 years, 0 months, 1 days

  • Research summary

    This study will use human cells obtained from a commercial supplier with the necessary ethical approvals and licences for collecting human biological samples in the UK. These approvals include those from the Human Tissue Authority (HTA), institutional review boards (IRB), and ISO-accredited collection protocols. The cell products may include human immune cells, tissue-derived cells, dissociated tumour cells, or laboratory-grown cancer cell lines. Donors may be healthy individuals or people with specific diseases, and all samples have been collected with appropriate consent. If immune cell products (such as leukopaks) are purchased, further purification will be carried out in our laboratory using specialised techniques.

    All samples will be securely stored in access-controlled laboratories and recorded in an electronic laboratory notebook (ELN) to track their arrival, processing, storage, use in experiments, and disposal. Some samples may be stored for up to two years to allow for the step-by-step nature of the study and donor-specific experimental requirements. All storage and handling procedures follow strict standard operating protocols (SOPs) and are subject to audits.

    As part of the research, some immune cells will be genetically modified to remove or introduce specific genes using advanced techniques such as CRISPR/Cas9. To confirm these modifications, we will perform targeted DNA sequencing. Further experiments will use genome-wide transcriptional analyses to assess changes in gene expression. All data will be securely stored, and all procedures will follow SOPs and be audited.

    The modified and unmodified cells will be tested in various experiments to assess their function. Some experiments will be short-term (about a week), while others may involve cell cultures maintained for up to three weeks. Some cells will be cryopreserved for later experiments.

    This research aims to improve our understanding of immune cell function and may contribute to the development of advanced cell and gene therapies.

  • REC name

    Yorkshire & The Humber - Leeds East Research Ethics Committee

  • REC reference

    26/YH/0152

  • Date of REC Opinion

    3 Aug 2026

  • REC opinion

    Favourable Opinion